The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
